Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology.

Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.

The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.